[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Money for antivirals", "description": "Money for antivirals, $3.2 billion\nhttps://www.washingtonpost.com/health/2021/06/17/drugs-for-covid/?utm_campaign=wp_to_your_health&utm\n\nAnthony S. Fauci, David Kessler, chief science officer for the covid-19 response\n\nReinvigorate the nation\u2019s antiviral program\n\nand test whether existing drugs show promise\n\nDavid Kessler\n\nWe need this set of tools to close out this pandemic.\n\nThe hard thing is to recognize with all the success, there\u2019s still several hundred deaths a day.\n\nCoronavirus first, then other potential pandemic viruses\n\nPre orders for this pandemic, before they have been shown to work\n\nAnn Kwong, virologist, (hepatitis C antiviral)\n\nInvestors are totally uninterested in antivirals. \n\nWhat they really want is a chronic treatment\n\nNobody ever gets cured of high cholesterol\n\nAntivirals, 5 to 10 days\n\nLast week, administration committed $1.2 billion\n\n1.7 million doses of molnupiravir (if approved)\n\nMerck and Ridgeback\n\nEffect of Ivermectin on Anopheles gambiae Mosquitoes Fed on Humans: The Potential of Oral Insecticides in Malaria Control \n\nhttps://academic.oup.com/jid/article/202/1/113/888773\n\nit was licensed for human use and was used in mass drug administration programs\n\nto control river blindness; it was administered to  more than 80 million adults and children. \n\nThe drug has proven to be safe. \n\nDoses up to 10 times the approved limit are well tolerated by healthy volunteers\n\nAdverse reactions are few and usually mild\n\nBarcelona Institute for Global Health\n\nhttps://www.isglobal.org/en/healthisglobal/-/custom-blog-portlet/questions-and-answers-about-ivermectin-and-covid-19/2877257/0\n\nMore than three billion treatments have been distributed in the context of the Mectizan Donation Program alone\n\nWith an excellent safety profile. \n\nMost adverse reactions are mild, transitory\n\nand associated with parasite death rather than with the drug itself.\n\nDr Soumya Swaminathan\n\nhttps://www.ndtv.com/india-news/coronavirus-ivermectin-efficacy-safety-most-important-top-who-scientist-warns-against-ivermectin-use-2439290\n\nSafety and efficacy are important when using any drug for a new indication. \n\nWHO recommends against use of 'ivermectin' for COVID-19 except within clinical trials\n\nBram Rochwerg, McMaster University\n\nCo-chair, WHO panel that reviewed ivermectin\n\nhttps://www.reuters.com/article/us-health-coronavirus-ivermectin-idUSKBN2BN2HH\n\nWe certainly need more data in order to make informed decisions\n\nWe did see an increase in adverse effects in patients that were randomised to ivermectin\n\nRepurposed drugs, there can be more harm than any good\n\nMerck Statement on Ivermectin use During the COVID-19 Pandemic\n\nhttps://www.merck.com/news/merck-statement-on-ivermectin-use-during-the-covid-19-pandemic/\n\nA concerning lack of safety data in the majority of studies.", "link": "https://www.youtube.com/watch?v=Of5_oiuqDp8", "date_published": "2021-06-20 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]